Restart Life Sciences Corp.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Restart Life Sciences Corp. (NMLSF) develops and commercializes innovative therapies focused on mitochondrial dysfunction and age-related diseases. The company offers a pipeline of small molecule drug candidates targeting conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders; its lead product, RESTART-001, is a novel mitochondrial modulator in preclinical development for cognitive impairment. Additional services include research collaborations and licensing agreements for proprietary compounds derived from its Restart platform technology. Founded in 2022 and headquartered in Vancouver, Canada, Restart Life Sciences operates primarily in North America with expansion into European clinical trial networks targeting biotech investors and pharmaceutical partners. In late 2024, the company completed a C$15 million Series A funding round led by LifeSci Venture Partners to advance RESTART-001 into Phase 1 trials; it also announced a strategic partnership with the University of British Columbia for mitochondrial biomarker validation. These developments mark a significant shift from early-stage discovery to clinical advancement, with no major acquisitions or name changes reported in the past two years.
Company News
Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth
Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors
Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods
Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap
Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY
Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods
Restart Life Subsidiary Holy Crap Foods Marks New International Expansion Milestone with Bahamas On-Demand App Launch
Restart Life Sciences Appoints Inez Ho as Chief Financial Officer
Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering
Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio
Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors
Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY
Restart Life Advances Holy Crap Growth Strategy with New Protein SKU Nearing Commercialization
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Launches on Walmart Canada's Digital Marketplace